RNLXD (Renalytix) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNLXD Renalytix PLC RNLXD
46 GF Score
Price $4.11
GF Value $7.75
! 3 Warning Signs
View Full Analysis

What is Renalytix 5-Year Yield-on-Cost %?

Renalytix RNLXD +0.46% 46 5-Year Yield-on-Cost % is 0.00 as of Aug. 06, 2026. GuruFocus rates RNLXD with a GF Score™ of 46/100 and a GF Value™ of $7.75. The stock has 3 warning signs investors should review. Among 275 Healthcare Providers & Services companies, Renalytix ranks worse than 363636% on this metric.

Renalytix's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Renalytix's 5-Year Yield-on-Cost % or its related term are showing as below:



RNLXD's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.86
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Renalytix  (OTCPK:RNLXD) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Renalytix 5-Year Yield-on-Cost % Related Terms


RNLXD vs VEEV, BTSG, HQY: 5-Year Yield-on-Cost % Comparison

For the Health Information Services subindustry, Renalytix's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Renalytix's 5-Year Yield-on-Cost % falls into.


RNLXD
46GF Score
Renalytix PLC RNLXD
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Renalytix is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Renalytix (RNLXD) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #999999 out of 275 companies in the Healthcare Providers & Services industry.
Is Renalytix's 5-Year Yield-on-Cost % too high?
Renalytix's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Renalytix ranks #999999 out of 275 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Renalytix has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #999999 out of 275 companies for 5-Year Yield-on-Cost %. This places Renalytix in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.86, based on 275 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (RNLXD) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $7.75, compared to a current price of $4.11 — trading 47% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Renalytix's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Renalytix (RNLXD), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renalytix (RNLXD) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of $4.11 is trading 47% below its estimated GF Value™ of $7.75.

Key valuation signals for RNLXD:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $7.75 vs. price of $4.11 (47% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score

Get the complete analysis for RNLXD

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$7.75
GF Value